Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Summary

The generation of aligned myocardial tissue is a key requirement for adapting the recent advances in stem cell biology to clinically useful purposes. Herein we describe a microcontact printing approach for the precise control of cell shape and function. Using highly purified populations of embryonic stem cell derived cardiac progenitors, we then generate anisotropic functional myocardial tissue.

Abstract

Advanced heart failure represents a major unmet clinical challenge, arising from the loss of viable and/or fully functional cardiac muscle cells. Despite optimum drug therapy, heart failure represents a leading cause of mortality and morbidity in the developed world. A major challenge in drug development is the identification of cellular assays that accurately recapitulate normal and diseased human myocardial physiology in vitro. Likewise, the major challenges in regenerative cardiac biology revolve around the identification and isolation of patient-specific cardiac progenitors in clinically relevant quantities. These cells have to then be assembled into functional tissue that resembles the native heart tissue architecture. Microcontact printing allows for the creation of precise micropatterned protein shapes that resemble structural organization of the heart, thus providing geometric cues to control cell adhesion spatially. Herein we describe our approach for the isolation of highly purified myocardial cells from pluripotent stem cells differentiating in vitro, the generation of cell growth surfaces micropatterned with extracellular matrix proteins, and the assembly of the stem cell-derived cardiac muscle cells into anisotropic myocardial tissue.

Introduction

Despite recent advances in medical therapy, advanced heart failure remains a leading cause of mortality and morbidity in the developed world. The clinical syndrome arises from a loss of functional myocardial tissue and subsequently an inability of the failing heart to meet the metabolic demands of affected individuals. Since the heart has a limited regenerative capacity, autologous heart transplantation is the only current clinically accepted therapy directly aimed at replenishing lost functional heart tissue. Significant drawbacks of heart transplantation, including a limited number of donor hearts and the need for long-term immunosuppressive therapy, preclude the wide spread use of this therapy. As a result, medical therapy has been the mainstay of treatment for patients with heart disease. A major challenge in drug development is the identification of cellular assays that accurately recapitulate normal and diseased myocardial physiology in vitro.

The recent convergence of stem cell biology and tissue engineering technology raises new promising avenues for cardiac regeneration. Generating functional myocardial tissue from a renewable patient-specific source would be a major advance in the field. This would allow for the development of disease specific cellular assays for drug development and discovery and would lay the foundation for cardiac regenerative medicine. Human embryonic stem (ES) cells and, more significantly, human induced pluripotent stem (iPS) cells represent a potentially renewable patient-specific source of ventricular progenitor cells and mature ventricular myocytes. The combination of stem cell biology and tissue engineering strategies addresses this problem by generating functional heart tissue in vitro that can be used in the development of cellular assays for drug discovery or in cardiac regenerative approaches for the treatment of advanced heart failure.

A central challenge in cardiac regeneration has been the identification of an optimal cell type. A wide array of cells have been studied¹, however to date, although different multipotent cardiogenic precursors from various sources have been discovered, the identification of a cell source that meets critical requirements such as commitment to the myogenic cell fate, maintenance of the capacity to expand in vivo or in vitro and composition to a functional myocardial tissue has proven to be a central problem². We have previously described a double transgenic murine system that enables the isolation of highly purified populations of committed ventricular progenitors (CVP) from ES cells differentiating in vitro. We generated a novel double transgenic mouse that expresses the red fluorescent protein dsRed under the control of an Isl1-dependent enhancer of the MEF2c gene and the enhanced green fluorescent protein under the control of the cardiac-specific Nkx2.5 enhancer. Based on this two-colored fluorescent reporter system, first and second heart field progenitors from developing ES cells can be isolated by means of Fluorescence Activated Cell Sorting (FACS) according to their expression of MEF2c and Nkx2.5 genes. CVP resemble cardiac myocytes based on the expression patterns of myocardial markers and structural and functional qualities³, what offers great promise for cardiac tissue regenerative purposes.

Although there have been many advances in the field of tissue engineering, mimicking native cellular architecture remains a key challenge. Conventional methods to address this challenge include seeding biological or synthetic scaffolds with cells in vitro. Due to a number of disadvantages of scaffolds, including rapid degradation, limited physical and mechanical stability and low cell density^1,4,5 , we have attempted to engineer scaffold-less tissue. Although cardiac cells can modify their local microenvironment by the secretion of extracellular matrix proteins, they have a more limited capacity to organize themselves to rod shaped cardiac myocytes in the absence of extracellular cues. Thus, a template that provides cells appropriate spatial and biological cues to compose functional myocardial tissue is required. Microcontact printing addresses this challenge by providing a simple and inexpensive technique to precisely control cell shape, organization, and function^6-8, all of which are crucial for the generation of aligned functional myocardial tissue. It comprises the use of microtextured Polydimethylsiloxane (PDMS) stamps with feature sizes ranging down to 2 μm⁹ that enable the deposition of extracellular matrix proteins onto PDMS substrates in precise patterns and thus to affect cell adhesion spatially.

Herein, we propose to combine tissue bioengineering technology with stem cell biology to generate anisotropic functional myocardial tissue. Accordingly, we here demonstrate our recently published approach for the following: (1) the generation of micropatterned protein surfaces on PDMS substrates by microcontact printing for the generation of a template for aligned myocardial tissue, (2) the isolation of highly purified cardiac progenitors from ES cells differentiating in vitro, and (3) the combination of both techniques to generate aligned functional myocardial tissue.

Protocol

The protocol to generate aligned functional myocardial tissue can be divided into three major parts. The fabrication of the micropatterned master using soft lithography techniques is not considered part of the following protocol but can be made based on established method⁶.

1. Microcontact Printing of Fibronectin onto PDMS Substrates

1. Mix Sylgard 184 (Dow Corning) PDMS elastomer at a 10:1 base to curing agent ratio and degas the assembly using a desiccator to eliminate any air bubbles.
2. Cure PDMS against a previously fabricated master with 20 μm wide and 2 μm tall ridges, separated by 20 μm spacing for either 2 days at room temperature or 4 hr at 65 °C to obtain microtextured PDMS stamps.

* Curing in a desiccator is highly recommended to eliminate any air bubbles.

3. Spin coat PDMS onto glass cover slips (e.g. 22x22 mm) at 5,000 rpm for 2 min using a Headway Spin Coater to produce thin and even PDMS substrates of 15 μm thickness.
4. Clean stamps with 70% Ethanol to remove dust and dirt particles. Let them air dry.

* Stamps can be used several times, however, renewing PDMS stamps on a regular basis is recommended due to a surface abrasion over time.

5. Place stamps in a SPI Plasma-Prep II Plasma Cleaner and process for 1 min at 275 mTorr to render PDMS surfaces hydrophilic.

* Oxygen plasma treatment should be watched. Longer treatment times can result in cracking of the elastomer.

6. Sterilize stamps with 70% Ethanol for 1 min. Dry quickly with compressed air.

* Further steps should be performed in a biological safety cabinet to maintain sterility.

7. Cover stamp surfaces with Fibronectin solution (50 μg/ml in ddH₂O). Let it adsorb at least 10 min.
8. Shake off Fibronectin solution from stamps and dry quickly with compressed air.
9. Establish conformal contact between stamps and PDMS substrates for 2 min and press firmly.
10. Rinse micropatterned substrates with ddH₂O. Store them in ddH₂O for a maximum of 2 weeks at 4 °C unless initially used. Store PDMS stamps in ddH₂O.

2. Maintenance of Double Transgenic Embryonic Stem Cell Lines

First, prepare the following media for culturing mouse ES cells:

Mouse Embryonic Fibroblast (MEF)-Medium: Dulbecco's Modified Eagle Medium (DMEM), 10% Fetal Bovine Serum (FBS) ES cell- or Differentiation-grade, 1% Penicillin-Streptomycin (P/S)

Embryonic Stem Cell (ESC)-Medium: DMEM, 15% FBS ES cell-grade, 1% Non-Essential Amino Acids (NEAA), 0.5% P/S, 0.2% Leukemia Inhibitory Factor (LIF), 0.0007% 2-Mercaptoethanol (2-ME)

1. Coat 6-well plates with sterile 0.1% Gelatin in ddH₂O and let it adsorb 15 min at 37 °C.
2. Add MEFs from a thawed aliquot to 50 ml PBS in a conical tube and centrifuge them at 1,000 rpm for 5 min. Resuspend MEFs in MEF-medium.
3. After adsorption, aspirate excess Gelatin and add MEFs into the wells. Allow MEFs 1 day to attach.

* An aliquot of 10 million MEFs suffices for 3 6-well plates.

4. When MEFs have attached, add ES cells from a thawed aliquot to 50 ml PBS in a conical tube and centrifuge them at 1,000 rpm for 5 min. Resuspend ES cells in ESC-medium and add them to the wells containing MEFs. Culture ES cells in ESC-medium until confluence is reached.

* Once ES cells have reached confluence, passaging is required to avoid overgrowth and to maintain ES cell colonies.

5. Prepare ES cells for passaging. Aspirate ESC-medium and wash once with sterile PBS.
6. Aspirate PBS and add 500 μl of Trypsin. Process 3.5 min at 37 °C.
7. Pipette the Trypsin solution up and down several times to break down ES cell colonies and neutralize it with 500 μl of ESC-medium.
8. Passage ES cells according to your desired ratio, e.g. transfer 33 μl to another well with previously prepared MEFs to passage 1/30. Maintain ES cells in ESC-Medium.

* A passage ratio of 1/30 allows ES cells to reach confluence within 3 days. Passage ES cells according to your in vitro differentiation schedule.

3. In vitro Differentiation of Double Transgenic Embryonic Stem Cell Lines and Isolation and Seeding of Cardiac Progenitors

First, prepare the following media required for the in vitro differentiation of ES cells:

Adaptation-Medium: Iscove's Modified Dulbecco's Medium (IMDM), 15% FBS ES cell-grade, 1% NEAA, 0.5% P/S, 0.2% LIF, 0.0007% 2-ME

Differentiation-Medium: IMDM, 15% FBS Differentiation-grade. 1% NEAA, 0.5% P/S, 0.35% of 0.1M Ascorbic Acid, 0.0007% 2-ME

1. Start in vitro differentiation when ES cells have reached confluence. Coat 10 cm culture dishes with sterile 0.1% Gelatin in ddH₂O and let it adsorb 15 min at 37 °C.

* Be aware of the duration of the in vitro differentiation process. It takes 8 days until cardiac progenitors can be isolated. Plan your experiments accordingly.

2. Harvest ES cells as before. After adsorption, aspirate excess Gelatin and add approximately 1/3-1/2 of the ES cell suspension to prepared culture dishes containing Adaptation-medium. Culture cells for 2 days.

* Choose the amount of ES cells for adaptation according to your experiments.

3. Harvest adapted ES cells into a 50 ml conical tube containing PBS using 1. 5 ml of Trypsin. Centrifuge dissociated ES cells at 1,000 rpm for 5 min and resuspend them in Differentiation-medium.
4. Make embryoid bodies (EBs) of approximately 1,000 cells per 10 μl drop in 15 cm culture dishes using a multi-channel pipette. Invert the plates and culture EBs as hanging droplets for 2.5 days at 37 °C.
5. After 2.5 days, pool EBs of 6-8 15 cm culture dishes into one using Differentiation-medium and culture them for a further 3.5 days at 37 °C.
6. After 3.5 days, collect EBs in a conical 50 ml tube and let them sink to the bottom for approximately 5 min. Suck up the supernatant and wash EBs with sterile PBS. Let EBs sink again to the bottom for approximately 5 min.
7. Dissociate EBs by processing them with 2. 5 ml of Trypsin for 2 min in a water bath at 37 °C shaking the tube softly. Then, add 2. 5 ml of sterile PBS to the Trypsin solution and pipette up and down with a 10 ml serological pipette approximately 8-10 times to break down cell clusters. Neutralize Trypsin with 10 ml of FACS buffer containing 7.5% FBS ES cell- or Differentiation-grade and 0.01% DAPI in PBS.
8. Centrifuge dissociated EBs at 1,000 rpm for 5 min and resuspend them in approximately 1 ml of FACS buffer. Pipette up and down with a 1 ml pipette approximately 8-10 times to break down cell clusters.

* Add FACS buffer according to the estimated amount of dissociated EBs. Too highly concentrated cells may clog during FACS and too low concentrated cells may prolong FACS time unnecessarily.

9. Transfer cells to a sterile round-bottom tube with a 35 μm cell strainer to obtain a single cell suspension.
10. Sort differentiated ES cells using a FACSAria Flow Cytometer and obtain purified populations of CVP.

*We developed a multi-step gating strategy to isolate highly purified colored cells. In brief, we first gate on Forward Scatter Amplitude (FSC-A) and Side Scatter Amplitude (SSC-A) (Figure 1A). This allows us to separate whole cells from cellular debris. We then gate on FSC-A and Forward Scatter-Width (FSC-W) (Figure 1B). This allows us to isolate cell singlets from doublets and other cellular aggregates. We then gate on SSC-A and Side Scatter-Width (SSC-W) (Figure 1C). This increases the purity of cell singlets. We then gate on DAPI staining to isolate viable cells (DAPI-negative) from non-viable cells (Figure 1D). We then gate on Phycoeryhthrin Amplitude (PE-A) and PE-Cyanine dye 7 Amplitude (PE-Cy7-A) to obtain true red-positive (R⁺) and true red-negative (R^-) cells and to exclude autofluorescent red-negative cells (Figure 1E). R⁺ and R^- cells are then gated separately on Fluorescein isothiocyanate Amplitude (FITC-A) and PE-A to sort true green-positive (G⁺) and true green-negative (G^-) cells within these populations (Figure 1F+1G). This results in 4 populations of cells as follows: R⁺G⁺, R⁺G^-, R^-G⁺ and R^-G^- (Figure 1H).

11. Passivate micropatterned substrates with 1% Pluronic F-127 in ddH₂O for 10 min. Then, wash them 3x with sterile PBS.

* Pluronic F-127 is a surfactant that blocks cell adhesion. It supports confinement of cell adhesion to micropatterned area.

12. Attach PDMS gaskets around the patterned region and press firmly. Then, seed CVP onto Fibronectin micropatterned substrates.

Results

FACS-purification of in vitro differentiated ES cells revealed four distinct populations of progenitors (Figure 1). The presence of micropatterned Fibronectin was confirmed by immunofluorescence microscopy that displayed a complete transfer of continuous Fibronectin lines (Figure 2). Plating of FACS-isolated progenitors onto Fibronectin micropatterns resulted in alignment of the R⁺G⁺ and part of the R^-G⁺ populations. Although Pl...

Discussion

In this protocol, we presented a method to isolate purified populations of cardiogenic progenitors and to seed them on micropatterned Fibronectin substrates what allows them align and take a cardiac myocyte-like rod shape. Normal cellular organization is critical for normal tissue function^8,10 , in particular for myocardial tissue. Cardiac myocytes have been shown to develop improved mechanical^11,12 and electrophysiological properties^11,13 when forming anisotropic cell arrays. Sinc...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
L-Ascorbic Acid	Sigma-Aldrich	A4544	Prepare 0.1M solution in ddH2O
Desiccator, Vacuum 10 inch	Nova-Tech International, Inc.	55206
4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI)	Life Technologies	D1306
Dulbecco's Modified Eagle Medium	Thermo Scientific	SH30022.01
DPBS	Gibco	14190
FACSAria II Flow Cytometer	BD Biosciences
Fetal Bovine Serum ES cell-grade	Gemini Bio-Products	100-106
Fetal Bovine Serum Differentiation-grade	Gemini Bio-Products	100-500
Fibronectin from bovine plasma	Sigma-Aldrich	F4759	Solubilize to 1 mg/ml in ddH2O
Fisherfinest Premium Cover Glass 22x22mm	Fisher Scientific	12-548-B
Gelatin from porcine skin	Sigma-Aldrich	G1890	Prepare 0.1% solution in ddH2O
Headway Spin Coater	Headway Research, Inc.	PWM32-PS-CB15
Iscove's Modified Dulbecco's Medium	Thermo Scientific	SH30228.01
Leukemia Inhibitory Factor	Self-prepared from LIF-secreting cell lines		Prepare 500x stock solution
MEM Non-Essential Amino Acids	Gibco	11140-050
2-Mercapt–thanol	Sigma-Aldrich	M6250
Mouse Embryonic Fibroblasts	Harvested from day 12-15 mouse embryos
Penicillin-Streptomycin	Gibco	15140-122
Pluronic F-127	Sigma-Aldrich	P2443	Prepare 1% solution in ddH2O
Round-Bottom Tube with 35 μm cell strainer	BD Biosciences	352235
SPI Plasma-Prep II Plasma Cleaner	SPI Supplies	11005-AB
Sylgard 184 Silicone Elastomer Kit	Dow Corning	184 SIL ELAST KIT 0.5KG
0.25% Trypsin-EDTA	Gibco	25200-056
Vacuum Gauge	SPI Supplies	11019-AB